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tissue-type plasminogen activator-
primed human ipSc-derived neural 
progenitor cells promote motor 
recovery after severe spinal cord 
injury
Yasuhiro Shiga1,2, Akina Shiga2, Pinar Mesci3, HyoJun Kwon1, Coralie Brifault1,4, 
John H. Kim1,5, Jacob J. Jeziorski3, Chanond nasamran6, Seiji ohtori2, Alysson R. Muotri3, 
Steven L. Gonias4 & Wendy M. campana1,7*
the goal of stem cell therapy for spinal cord injury (Sci) is to restore motor function without 
exacerbating pain. Induced pluripotent stem cells (iPSC) may be administered by autologous 
transplantation, avoiding immunologic challenges. Identifying strategies to optimize iPSC-derived 
neural progenitor cells (hiNPC) for cell transplantation is an important objective. Herein, we report 
a method that takes advantage of the growth factor-like and anti-inflammatory activities of the 
fibrinolysis protease, tissue plasminogen activator tPA, without effects on hemostasis. We demonstrate 
that conditioning hiNPC with enzymatically-inactive tissue-type plasminogen activator (EI-tPA), prior 
to grafting into a T3 lesion site in a clinically relevant severe SCI model, significantly improves motor 
outcomes. EI-tPA-primed hiNPC grafted into lesion sites survived, differentiated, acquired markers 
of motor neuron maturation, and extended βIII-tubulin-positive axons several spinal segments below 
the lesion. Importantly, only SCI rats that received EI-tPA primed hiNPC demonstrated significantly 
improved motor function, without exacerbating pain. When hiNPC were treated with EI-tPA in culture, 
NMDA-R-dependent cell signaling was initiated, expression of genes associated with stemness (Nestin, 
Sox2) was regulated, and thrombin-induced cell death was prevented. EI-tPA emerges as a novel agent 
capable of improving the efficacy of stem cell therapy in SCI.
Stem cell therapy may be effective for treating patients with spinal cord injury (SCI). Substantial work has been 
conducted with embryonic neural stem cells (NSC) in animal models of SCI1–3. An alternative approach is to graft 
induced pluripotent stem cells (iPSC), which are pre-conditioned to generate lineage committed neural progeni-
tor stem cells (NPC)4–6. iPSC are derived from skin5, dental pulp6–8, or blood cells9 and may be re-administered to 
patients by autologous transplantation. Grafting human iPSC-derived NPC (hiNPC) in patients with SCI avoids 
immunological and ethical complications associated with embryonic NSC.
hiNPC have shown efficacy in restoring motor function in rodent models of moderate lower thoracic (T9–
T10) SCI10–12. In a severe cervical rodent model of SCI, grafted iPSC-derived NSC developed axons, which 
emerged from the implantation site and formed synapses with host spinal cord neurons; however, significant 
recovery of motor function was not observed13. It is not clear whether this result reflects the NSC phenotype14, 
insufficient optimization of the grafting method, or the severity of the SCI model. Accordingly, more studies 
are needed to understand hiNPC biology and to improve methodologies for successful hiNPC transplantation. 
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The goal of this research project was to identify strategies for optimizing the efficacy of hiNPC as a treatment for 
severe SCI.
Tissue-type plasminogen activator (tPA) is an activator of fibrinolysis and globally approved drug for treating 
non-hemorrhagic stroke15. The activity of tPA in fibrinolysis and stroke is based on its function as a protease16; 
however, recombinant tPA also interacts with cellular receptors such as the N-methyl-D-aspartate Receptor 
(NMDA-R)17,18 and LDL Receptor-related Protein-1 (LRP1)19 to mediate changes in cell physiology that are 
independent of its protease activity and potentially relevant to the challenges of stem cell therapy. tPA is neuro-
protective towards cortical neurons20 and promotes neurite outgrowth in neurons and neuron-like cells by acti-
vating cell-signaling factors such as c-Src and ERK1/221,22. tPA also may regulate innate immunity by suppressing 
Toll-like Receptor responses23. These activities are replicated by enzymatically-inactive (EI) tPA.
In the normal CNS, tPA is present in pre-synaptic vesicles24 and secreted by neuronal growth cones, where 
it functions to promote synaptic plasticity, axonal elongation, and path-finding25. tPA expression is increased in 
Purkinje neurons during motor task training and has been implicated in activity-based cerebellar motor learn-
ing26. Collectively, these studies demonstrate that in addition to its role in fibrinolysis, tPA functions like a growth 
factor, eliciting receptor-mediated effects on cell-signaling and gene expression in various cells including motor 
neurons and neuron-like cells. The activity of tPA in iPSC and hiNPC has not been examined.
In this study, we tested whether the growth factor-like activities of EI-tPA may be exploited to improve the 
efficacy of transplanted iPSC-derived hiNPC in severe SCI in rats. We used a severe T3 SCI model (T3SCI), which 
induces motor loss and neuropathic pain27 and thus, models SCI in patients28. Our results demonstrate significant 
improvement in motor function in rats grafted with hiNPC, only when these cells are primed by treatment with 
EI-tPA. Cell fate mapping confirmed axon extension and differentiation of EI-tPA-treated hiNPC into motor 
neurons. EI-tPA induced cell-signaling in hiNPC in vitro and regulated expression of genes in hiNPC, including 
Nestin and Sox2. We conclude that EI-tPA primes hiNPC and improves functional regeneration in SCI. Because 
these activities are elicited with the EI derivative of tPA, abnormalities in hemostasis are not a concern.
Results
hiNPC respond to EI-tPA in vitro. We characterized hiNPC, which are iPSC-derived, lineage committed 
NPC5,6. Immunofluorescence analysis demonstrated that hiNPC (C6WT183) in culture express the stemness bio-
marker, Nestin, to a greater extent than human Schwann cells (hSC), which were analyzed as a control (Fig. 1a). 
RT-qPCR confirmed that the mRNAs encoding Nestin and Sox2 are greatly enriched in hiNPC compared with 
hSC (Fig. 1b). The pre-neuronal marker, CD24, also was abundantly expressed by hiNPC. Thus, hiNPC expressed 
stem cell and pre-neuronal markers prior to grafting, as anticipated.
Next, we examined whether EI-tPA elicits cell-signaling in cultured hiNPC. hiNPC were serum-starved 
and subsequently treated with EI-tPA (0–12 nM). In hiNPC treated with 12 nM EI-tPA, the survival-promoting 
cell-signaling factor, Akt (M.W.60 kDa), was phosphorylated within 15 min (Fig. 1c). MK-801 blocked Akt phos-
phorylation by EI-tPA, suggesting an essential role for the NMDA-R19,21,23. Densitometry analysis of five separate 
experiments demonstrated that the increase in Akt phosphorylation induced by EI-tPA and the effects of MK-801 
were statistically significant (P < 0.05; Fig. 1d). EI-tPA (12 nM) also activated ERK1/2 (M.W. 42 and 44 kDa) in 
hiNPCs (P < 0.05; Fig. 1e,f).
We also identified the effects of EI-tPA on hiNPC gene expression. hiNPC were treated with 12 nM EI-tPA for 
48 h. Expression of the stemness biomarkers, Nestin and Sox2, was significantly increased (Fig. 1g). Expression 
of LRP1, which serves as a co-receptor in EI-tPA-induced NMDA-R-dependent cell-signaling19,22, also was 
increased, whereas CD24 was unchanged. In trypan blue exclusion assays, thrombin, a known inducer of neu-
ronal cell death29,30, dose-dependently decreased hiNPC viability (Fig. S1a). EI-tPA (12 nM) blocked cell death 
mediated by thrombin (5 units/mL) in cultured hiNPC (P < 0.05; Fig. S1b). Cell Death Elisa™ studies confirmed 
that the viability of hiNPC was decreased by thrombin and rescued by EI-tPA (P < 0.05 Fig. 1h). Increased expres-
sion of Sox2 provides one explanation for improved resistance of EI-tPA-treated hiNPC to apoptosis31.
To confirm that our results with EI-tPA and hiNPCs are representative of hiNPCs in general, we tested a sec-
ond iPSC-derived hiNPC line from a different patient (C5WT126). A similar characterization pattern, including 
expression of the stem cell biomarkers, Nestin, Pax6 and Brn2, was observed in both the first and second hiNPC 
clones (Fig. S2). When the second clone was treated with 12 nM EI-tPA, Akt was phosphorylated within 15 min 
and this response was blocked by MK801 (1.0 μM) (Fig. S3). Glycogen synthase kinase 3β (GSK-3β) was phos-
phorylated in response to EI-tPA, as was ERK1/2. These phosphorylation events also were inhibited by MK-801 
(Fig. S3), confirming an essential role for the NMDA-R19,21,23, as anticipated17,18,23.
hiNPC improve locomotor activity in severe SCI only when pre-treated with EI-tPA. Next, we 
suspended hiNPC in fibrin and grafted the cells into immunodeficient rats one week following T3 spinal cord 
compression injury (T3SCI). Histologically, T3SCI generates a band of disrupted parenchyma across the com-
pression site with partial cavitation27. Thirteen rats were grafted with GFP-expressing hiNPC that were pre-treated 
with EI-tPA (12 nM) for 15 min. Eleven rats were grafted with GFP-expressing hiNPC that were not treated with 
EI-tPA. Eleven additional control rats were grafted with cell-free vehicle. All grafts contained a lower concentra-
tion of thrombin, compared with that previously used13 given the potential for thrombin to cause cell stress and 
cell death (Fig. 1h). The grafting timepoint was selected for clinical relevance to SCI patients undergoing decom-
pression and stabilization32.
Rats subjected to T3SCI had complete hindlimb paralysis within a day after injury. T3SCI caused substan-
tial loss of motor function, when assessed two weeks post-injury, as determined using the Basso, Beattie and 
Bresnahan (BBB) locomotor scale (Fig. 2a)33. BBB scores were <2. By 3 weeks, rats without grafted hiNPC recov-
ered to a BBB score of 4 but failed to improve beyond a BBB score of 5 for the duration of the study (4 months), 
consistent with previous results27.
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Figure 1. Bioactivity of EI-tPA in hiNPC in vitro. (a) Representative IF microscopy images of hiNPCs and 
hSCs immunostained to detect Nestin (red) and labeled with DAPI (blue) (n = 3 per group). As a control, 
hiNPC were incubated with secondary antibody only and with DAPI (right-hand panel). Scale bar 40 µm. 
(b) mRNAs encoding Nestin, Sox2, and CD24 in hiNPC and hSCs. Human EID2 mRNA was quantified as a 
normalizer (*P < 0.05 by Student's t-test, mean ± SEM; n = 4). (c) hiNPC were treated with EI-tPA (0–12 nM) 
for 15 min (n = 3 independent studies). In some wells, MK801 (1 µM) was added prior to EI-tPA (n = 2 
independent studies). Equal amounts of cellular protein (20 µg) were subjected to immunoblot analysis to detect 
phospho-Akt and GAPDH. (d) Akt phosphorylation immunoblots were subjected to densitometry. Levels of 
phospho-Akt were standardized using GAPDH (*P < 0.05 by one-way ANOVA, Neuman Keuls post hoc test, 
mean ± SEM). (e) hiNPC in culture were treated with EI-tPA (0–12 nM). ERK1/2 phosphorylation and total 
ERK1/2 were determined. (f) Densitometry analysis of phospho-ERK1/2 and GAPDH (*P < 0.05 by one-way 
ANOVA followed by Neuman Keuls post hoc test, mean ± SEM; n = 3 independent experiments). (g) Cultured 
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Rats that were subjected to T3SCI and grafted with hiNPC demonstrated a trend towards improved BBB 
scores beginning at 3–6 weeks; however, throughout the 16-week observation period, statistical significance was 
not achieved. In rats grafted with EI-tPA-treated hiNPC, BBB scores were further improved and the effects of 
EI-tPA-treated hiNPC on motor function achieved statistical significance. BBB scores of approximately 15 were 
recorded at 16 weeks (P < 0.01; Fig. 2a). Representative video imaging of rats subjected to T3SCI (Movie S1) and 
grafted with EI-tPA-treated hiNPC demonstrated obvious improvements compared with rats that were grafted 
with untreated hiNPC (Movies S2, S3). The significant effects of EI-tPA on the efficacy of grafted hiNPC were 
confirmed by analyzing total body weight (Fig. 2b) and tibialis anterior leg muscle weight (Fig. 2c), parameters 
known to correlate with motor recovery following SCI34.
hiNPC survive and differentiate in injured spinal cords. Grafted hiNPC survived and filled the SCI 
lesion cavity. Immunostaining for hNu, which specifically detects human nuclei, showed a three-fold increase 
in the number of hiNPC in the EI-tPA-treated group (P < 0.05) 8 weeks after T3SCI, suggesting greater survival 
and/or hiNPC proliferation (Fig. 3a,b). At 16 weeks, the number of grafted hiNPC in the EI-tPA-treated group 
remained two-fold higher (P < 0.05; Fig. 3b). Importantly, the mean size of the hNu+ nuclei was significantly 
increased in grafts of EI-tPA-treated hiNPC, compared with animals that received untreated hiNPC (~40 µm vs. 
~25 µm) (P < 0.05; Fig. 3a,c). Nuclear hypertrophy is an indicator of cell maturation3.
Nestin is a nucleo-cytoplasmic shuttling protein that may serve as an indicator of hiNPC differentiation35. At 
8 weeks, Nestin immunoreactivity was most intense in the peri-nuclear area of GFP-expressing EI-tPA-treated 
hiNPC, however, untreated hiNPC demonstrated Nestin immunoreactivity only in cytoplasmic processes 
(Figs. 3d and S4). At 16 weeks, perinuclear nestin immunoreactivity was observed in hiNPC that were not 
EI-tPA-treated. Thus, hiNPC may have undergone a similar transition in nestin subcellular localization irrespec-
tive of whether EI-tPA is present. EI-tPA may have accelerated the transition.
To determine whether hiNPCs extend and integrate into the host spinal cord, we examined longitudinal sec-
tions beginning at the injury site and extending caudally βIII tubulin-positive axons emerged from the lesion 
site and co-localized with GFP immunoreactivity in rats grafted with untreated hiNPCs or EI-tPA-treated hiN-
PCs (Fig. 4a,b). Next, we compared transverse T7 sections isolated from rats grafted with untreated hiNPCs or 
EI-tPA-treated hiNPCs to determine whether EI-tPA promoted axonal extension. Although GFP immunoposi-
tivity was detected in the white and gray matter in both experimental groups, in rats grafted with EI-tPA-treated 
hiNPCs, GFP immunoreactivity appeared substantially increased in the T7 spinal segment (dorsal and ventral 
areas) (Fig. 4d,e). Quantification of total GFP-immunopositive tissue in the T7 ventral segment showed a 3-fold 
increase in rats grafted with EI-tPA-treated hiNPCs (P < 0.05; Fig. 4c). Given the size of the immunoreactive pro-
jections (<2 µM) and lack of co-localization of GFP with DAPI, the GFP most likely represents hiNPC-derived 
axons and not migrating glia.
To confirm that hiNPC expressed a neuronal phenotype, we performed dual-label immunofluorescence for 
GFP and βIII tubulin-positive projections in T7 transverse sections. SCI rats treated with hiNPCs in the absence 
of EI-tPA expressed some βIII tubulin (Fig. 4f) and GFP immunoreactivity (Fig. 4h) in the spinal ventral horn, 
however, minimal colocalization was apparent (Fig. 4j,l). By contrast, SCI rats grafted with EI-tPA-treated hiNPC 
robustly expressed βIII tubulin (Fig. 4g) and GFP immunoreactivity (Fig. 4i) in the spinal ventral horn. The 
majority of GFP co-localized with βIII tubulin (Fig. 4k,m). These finding indicate that EI-tPA-treated hiNPC 
grafted into the lesion site extend neuronal projections four segments distal to the lesion site after 4 months.
Cell fate mapping studies at the lesion site revealed that hiNPC acquire a neuron phenotype. hiNPC identified 
by hNu+ (as shown in Fig. 3a) co-localized with the neuron specific cytoskeletal protein MAP2 in lesion sites 
(Fig. 5a). This was observed in both hiNPC grafts alone and EI-tPA-treated hiNPC grafts. At 8 weeks, the motor 
neuron marker, choline acetyltransferase (ChAT), co-localized with GFP and hNu (Fig. 5b) in EI-tPA-treated 
hiNPCs. Motor Neuron and Pancreas Homeobox 1 (HBP/MNX1), a second motor neuron marker found in 
nuclei36, also co-localized with GFP and hNu (Fig. 5c). GFP-expressing, EI-tPA-treated hiNPC failed to 
co-localize with GFAP in the lesion site (Fig. 5d) and distal to the lesion site (Fig. 5e), suggesting that the hiNPC 
did not become astrocytes.
Nociception in rats subjected to T3SCI and treated with hiNPC with and without EI-tPA. To 
test whether rats grafted with hiNPC develop altered sensation to light touch, which may indicate exacerba-
tion of injury-associated neuropathic pain, we performed hindpaw tactile allodynia testing 8 weeks post-T3SCI, 
when motor improvement was underway. Prior to T3SCI, rats had a mean paw withdrawal threshold (PWT) 
of 15.7 ± 0.9 g (Fig. 6a). Eight weeks after T3SCI, the PWT was reduced to 8.1 ± 0.9 g in rats that received no 
hiNPC, indicating allodynia. Importantly, the extent and magnitude of allodynia was not altered by hiNPC or by 
EI-tPA-treated hiNPC through the duration of the study (8–16 weeks post-T3SCI).
To mine for changes in gene expression that might predict altered somatosensory function, we performed 
RNA-Seq analysis of DRGs 16 weeks post-T3SCI and grafting of hiNPCs. Control animals were subjected to 
T3SCI but not grafted. Differentially expressed (DE) genes were identified and expressed as logFC (Fig. 6b). 
Amongst the top 25 regulated genes, RNA-Seq identified the known pain-related genes, KCNN1 and VIP 
hiNPC were treated El-tPA (12 nM) or vehicle for 48 h. RT-qPCR was performed to compare mRNA levels 
for Nestin, Sox2, CD24, and LRP1 (*P < 0.05 by Student t-test, mean ± SEM; n = 5 replicates per group;). 
(h) hiNPC were treated with thrombin (5 units/mL), in the presence of vehicle or 12 nM EI-tPA for 18 hours. 
Cell extracts were analyzed using the Cell Death ELISA (*P < 0.05 by one-way ANOVA with a Neuman Keuls 
post-hoc test, mean ± SEM; n = 3–8 replicates per group).
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(Table S1). To validate KCNN1 and VIP as genes regulated in the DRG in response to hiNPC grafting at the SCI 
site, RT-qPCR was performed. At 8 weeks, expression of KCNN1 or VIP was not significantly different in the 
control and hiNPC-treated groups (Fig. 6c). However, 16 weeks post-SCI, KCNN1 mRNA was decreased in the 
hiNPC-treated group, whereas VIP mRNA was increased (P < 0.05; Fig. 6c). These changes in DRG gene expres-
sion suggest that hiNPC may, in the long term, induce changes in somatosensory function that were not detected 
in our tactile allodynia experiments.
Forepaw tactile allodynia was also studied since neuropathic pain may be observed above or at the level of 
injury27. Prior to T3SCI, control rats had a mean forepaw PWT of 15.1 ± 1.0 g (Fig. 5d). Four weeks after SCI, 
the PWT in control rats was 9.2 ± 0.8 g. Rats grafted with hiNPC or EI-tPA-treated hiNPC showed no significant 
differences in forepaw PWTs over the 16-week monitoring period, indicating that neuropathic pain was not exac-
erbated or mitigated by the hiNPC.
Figure 2. hiNPC primed with EI-tPA enhance motor recovery in T3SCI after four months. (a) BBB scores 
in rats grafted with hiNPC (yellow) or EI-tPA-treated hiNPC (green) or vehicle (no cell control) (blue) after 
T3SCI (**P < 0.01 by repeated measures ANOVA followed by Bonferroni post-hoc test, mean ± S.E.M; n = 14 
animals). (b) Body weights in rats grafted with vehicle (no cell control) (blue), hiNPC (yellow), or EI-tPA-
treated hiNPC (green) after T3SCI (*P < 0.05 by one-way ANOVA and Tukey's post-hoc test, mean ± S.E.M; 
n = 18 animals). (c) Tibialis anterior muscle weight in rats grafted with vehicle (no cell control) (blue), hiNPC 
(yellow) or EI-tPA-treated hiNPC (green) after T3SCI (**P < 0.01; ***P < 0.001 by one-way ANOVA and 
Tukey's post-hoc test, mean ± S.E.M; n = 18 animals).
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Discussion
This study demonstrates that the efficacy of hiNPC in facilitating SCI repair and recovery of motor function may 
be significantly improved by treating the hiNPC with EI-tPA. Compared with untreated hiNPC, EI-tPA-treated 
hiNPC demonstrated improved survival and maturation at the SCI lesion site and a significant increase in the 
number of axons projecting caudally into spinal segment T7. Although a trend towards improved motor func-
tion was observed in animals grafted with untreated hiNPC, the magnitude and extent of the response to hiNPC 
grafting was statistically significant only when the hiNPC were EI-tPA-primed. To our knowledge, this is the first 
study showing beneficial effects of EI-tPA on neural progenitor cells and in particular, hiNPC, in vitro and in vivo.
In studies with cells in culture, we showed that EI-tPA activates cell-signaling cascades in hiNPC that are asso-
ciated with cell survival and dependent on the NMDA-R. In addition to its role as an ionotropic glutamate recep-
tor, the NMDA-R is a known cell-signaling receptor for tPA, which may function in conjunction with LRP117–19,22. 
EI-tPA increased expression of LRP1 mRNA in hiNPC, which may support or amplify tPA-dependent cell signa-
ling and cell survival. LRP1 is a potent cell survival receptor for Schwann cells37. Cooperation between LRP1 and 
the NMDA-R in EI-tPA-signaling in hiNPC suggests that this receptor system is conserved in diverse cell types.
When hiNPC were challenged with thrombin in vitro, an inducer of cell death in neurons29,30 and a compo-
nent of the SCI grafting cocktail, EI-tPA protected the hiNPC from cell death. EI-tPA-dependent cell signaling 
also increased expression of stem cell markers, Sox2 and Nestin. Accumulating evidence suggests that when 
stem cells express increased levels of the stemness factors, Sox2 and Oct4, they have a greater intrinsic resistance 
towards apoptosis31. Pre-treating hiNPC with EI-tPA prior to grafting may protect these cells from the challeng-
ing, pro-inflammatory SCI microenvironment. The hypothesis that EI-tPA may promote hiNPC survival in vivo 
in SCI is supported by the work of LeMarchand et al.38, demonstrating neuroprotective effects of tPA on stressed 
postnatal neurons. Nonetheless, the effects we observed in our studies with EI-tPA and hiNPC in culture is likely 
dictated by the in vitro niche and should be interpreted with this perspective.
Figure 3. hiNPC survival and maturation in vivo are enhanced by EI-tPA. (a) Fluorescent images of the human 
nucleus marker, hNu+ (white), in T3SCI lesion sites with hiNPC and EI-tPA-treated hiNPC at 8 and 16 weeks. 
Each panel represents an individual rat. Scale bars for low power (200X) images in (a) are 200 µm and for insets are 
25 µm. (b) Quantification of hNu+ cells in lesions with hiNPC (yellow) and EI-tPA-treated hiNPC (green) at 8 and 
16 weeks (*P < 0.05 by Student's t-test, mean ± SEM; n = 3 per group). (c) Quantification of the size of hNu+ nuclei 
of EI-tPA-treated hiNPC versus untreated hiNPC (*P < 0.05 by Student's t-test, mean ± SEM; n = 3 per group). 
(d) Dual label immunofluorescence of GFP in hiNPCs (green) and the stem cell marker, Nestin (red), shows co-
localization in grafted hiNPC. Nuclei are labeled with DAPI (blue). Scale bars for images (400X) are 50 µm.
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Figure 4. EI-tPA promotes penetration of hiNPC axons into the ventral spinal T7 segment in vivo. (a) GFP-
expressing EI-tPA-treated hiNPC co-localized with axonal marker, βIII tubulin (Tuji) emerging from the 
grafting site after 4 months. DAPI labels nuclei (blue). Images represent 3 individual rats per group. Scale bar 
is 50 µm. (b) Representative higher magnification image of (a). Scale bar is 25 µm. (c) Quantification of GFP 
immunoreactivity in the host ventral T7 segment in rats grafted with EI-tPA-treated hiNPC versus untreated 
hiNPC (*P < 0.05 by Students t-test, mean ± S.E.M; n = 3 rats per group). Fluorescent images of graft derived 
GFP+ cells integrating into T7 spinal segments; (d) hiNPC or (e) EI-tPA treated hiNPC. Scale bar is 30 µm. Dual 
labeling immunofluorescence of βIII tubulin and GFP in T7 ventral spinal segments; (f,h,j,l) hiNPC or (g,i,k,m) 
EI-tPA treated hiNPC. Scale bar 50 µm.
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Figure 5. Cell fate mapping of EI-tPA treated hiNPC in vivo. (a) Dual label immunofluorescence showed co-
localization with hNu (white) and the neuron-specific marker, MAP2 (red), at the lesion site. Scale bar 25 µm. 
(b) Triple label immunofluorescence showed co-localization with ChAT (red), hNu (white) and GFP (green), 
revealing the presence of mature motor neurons at the lesion site by 8 weeks. Scale bar is 25 µm. (c) Triple 
label immunofluorescence showed co-localization of Mnx1 (red), hNu (white) and GFP (green), revealing the 
presence of mature motor neurons at the lesion site at 16 weeks. DAPI labels nuclei (blue). Scale bar is 25 µm. 
(d,e) Immunofluorescence showing GFP expressing hiNPC in the lesion site (low power) that is distinct from 
GFAP immunoreactive host astrocytes (red) at 8 weeks. Scale bar is 100 µm. (f) Higher power image distal to the 
lesion site. GFP expressing hiNPC were integrated into the host tissue and did not co-localize with GFAP (red) 
at 16 weeks. Scale bar 100 µm.
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Figure 6. Effects of hiNPC on sensory function following T3SCI. (a) Hindpaw tactile allodynia was studied 
from 8 to 16 weeks post-T3SCI. (n.s., by two-way repeated measures ANOVA followed by Bonferroni post-hoc 
analysis mean ± SEM; n = 4–6 rats per group). (b) Heat map of differentially abundant transcripts by RNA-Seq 
in L5 DRGs after T3SCI, with and without grafted hiNPC. Increased expression is shown in red and reduced 
expression is shown in blue. RNA-Seq transcripts and experimental groups are arranged by unsupervised 
hierarchical clustering. Genes in bold are of potential interest for future pain related studies. (c) Changes 
in expression of KCNN1 and VIP in L5 DRGs at 8 and 16 weeks post-T3SCI (*P < 0.05 by Students t-test, 
mean ± SEM; n = 2–3). (d) Forepaw tactile withdrawal thresholds from 8–16 weeks (n.s., two-way repeated 
measures ANOVA followed by Bonferroni post-hoc analysis, mean ± SEM; n = 4–6 rats per group).
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Although previous studies demonstrated the ability of NSC to promote recovery after SCI3,39, the cells used 
in these studies were derived from embryonic tissues, which raise ethical issues when translation into human 
patients is considered. Although iPSC-derived NSC are previously reported to develop axons and form synapses 
when transplanted into SCI lesions, significant functional motor recovery was not observed13. We further con-
firmed this observation in our studies using hiNPC that were not treated with EI-tPA. Differences in tissue origin, 
induction methods, injury severity, the level of the SCI lesion, and grafting factors may contribute to variation 
in the results observed when iPSC technology is applied as a therapeutic strategy for SCI4,10,11,13. Notably, we 
utilized a well-described retroviral method to reprogram fibroblasts into hiPSC4–6,40,41. We previously used these 
methods in several studies and did not observe any aneuploidy or genomic errors due to the reprogramming 
method4–6,42,43. However, as we consider transplantation of stem cell grafts for SCI therapeutically, methods utiliz-
ing non-integrating reprogramming methods might be suitable for clinical translation44.
In addition to observing improved motor function in animals grafted with EI-tPA-treated hiNPC, we observed 
decreased muscle atrophy. ChAT and MNX1-positive neurons were present in lesions sites grafted with hiNPC 
which is consistent with functional motor improvements. It is possible that EI-tPA caused the hiNPC to differ-
entiate into motor neurons at earlier time points. It is also possible that EI-tPA-treated hiNPC affected central 
pattern generators by activating key circuitry above the lesion site, which contributes to improved motor func-
tion45,46. Yet, the most striking result was the large number of axons penetrating into the T7 spinal ventral horn in 
the EI-tPA treated hiNPC group. Although there were GFP + structures in the T7 segment by the hiNPCs alone, 
they did not appear to be a neuronal phenotype, as they did not colocalize with an axonal marker, βIII tubulin. 
Whether this is due to the limited number and size of axonal projections or whether they differentiate into a glia 
phenotype remains unknown. However, the improvements we observed in motor function by EI-tPA priming can 
at least be partially explained by a greater density of axons. Importantly, host axons appeared to be more abun-
dantly expressed, suggesting the EI-tPA primed hiNPCs may improve host axon regeneration. Further studies are 
needed to confirm these hypotheses.
Notably, hiNPC did not worsen or improve “above” or “below” the lesion site pain-related behaviors. In pre-
vious studies that reported detrimental effects of stem cells on pain, the grafted NSC expressed astrocyte markers 
in vivo47. Our model system differs markedly in that we graft hiNPC directly into the lesion site, generating 
numerous mature neurons that extend many axons into the host spinal cord. There was also a possibility that 
“below-level” pain could now become consciously detectable pain after hiNPC treatment since hiNPC appeared 
to re-establish motor neural connectivity. However, we observed no detectable alterations in hindlimb sensation 
in rats grafted with hiNPC or hiNPC with EI-tPA, despite the improved motor recovery.
Although we did not see any differences in functional pain outcomes amongst hiNPC groups even when 
primed with EI-tPA in SCI rats, we performed RNA sequencing (RNA-Seq) studies in DRGs to determine 
whether changes in the molecular pain processing signature reflect hiNPC treatment after 16 weeks. We observed 
differential gene expression in 11 potential pain related processing genes that included VIP and KCNN1. 
Increased VIP mRNA has been associated with neuropathic pain48 and KCNN1 down regulation has been impli-
cated in pain hypersensitivity49. Importantly, these genes were unchanged in the DRGs after 8 weeks, but were 
significantly altered in rats grafted with hiNPC after 16 weeks. Changes in expression of these genes may justify 
future studies in which somatosensory testing is examined over longer periods of time following hiNPC grafting.
Methods
Neural progenitor cells (NPC) and human schwann cells (SC). Human iPSC were obtained from 
skin fibroblasts from two healthy patients, WT126 (one clone, C5) and WT83 (two clones, C6,C9) as previously 
described5,40–43. The study protocol was approved by the University of California, San Diego (UCSD) and the 
Salk Institute Institutional Review Board (IRB)/Embryonic Stem Cell Oversight Committee (ESCRO) commit-
tees. Studies were carried out in accordance with these relevant guidelines and regulations. Briefly, subjects were 
recruited through the University of California, San Diego Autism Center of Excellence from a pool of volunteers 
formerly included in previous brain imaging studies. After a complete description of the study was provided, writ-
ten informed consent was obtained from all adult subjects. Primary cultures of human SCs isolated from human 
spinal nerve were purchased from ScienCell Research Laboratories (#1700; Carlsbad, CA) and maintained in the 
manufacturer′s Schwann Cell Medium (#1701), as previously described50.
RNA isolation and qPCR. Cells or tissue were homogenized in lysis buffer and total RNA was extracted 
using the NucleoSpin® RNA kit (Macherey-Nagel). RNA was reverse-transcribed using the iScript cDNA syn-
thesis kit (Bio-Rad). qPCR was performed using TaqMan® gene expression products and an AB Step one Plus 
Real-Time PCR System (Applied Biosystems), as previously described23. The mRNAs analyzed for hiNPCs and 
hSCs included: Nestin (Hs04187831_g1), Sox2 (Hs04234836_s1), CD24 (Hs02379687_s1), LRP1 (Hs00233856_
m1), the turquoise module potassium channel related gene (KCNN1) (Rn00570904_m1). The mRNAs analyzed 
for dorsal root ganglia (DRGs) included: and vasoactive intestinal polypeptide, VIP (Rn01430567_m1). The rela-
tive change in mRNA expression was calculated using the 2ΔΔCt method and EID2 (Hs00541978_s1) and GAPDH 
(Rn01775763_g1) mRNA as internal normalizers for human cells and rat tissues respectively. EID2 is a stable 
reference gene for human iPSCs51. Control qPCR reactions were performed using samples that were not exposed 
to reverse transcriptase to verify the absence of genomic DNA contamination.
Cell signaling studies. hiNPC were transferred to serum-free medium for up to 6 h and then treated with 
EI-tPA or vehicle. When indicated, hiNPC were pre-treated with MK801 (1 µM; Tocris Bioscience) for 30 min. 
Immunoblot analysis was performed as described previously37,52.
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Cell death studies. hiNPC were plated in 96 well plates and exposed to thrombin (5 units/mL) with and 
without EI-tPA (12 nM). Cell death was determined using Cell Death Detection ELISAPLUS according to the man-
ufacturer's instructions (Roche).
Animals. Studies were performed using 38 adult female Foxn1rnu rats (150–160 g; Charles River, Wilmington, 
MA). We chose female rats for these studies because their bladders are more readily emptied following severe SCI. 
Inclusion of female subjects in SCI and pain studies is well supported53. Pain prevalence rates and descriptions of 
pain do not differ between male and female patients with SCI54,55.
Surgeries. Animals were housed individually with free access to food and water in a vivarium approved by 
the American Association for the Accreditation of Laboratory Animal Care (AAALC). All animal studies were 
carried out according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) 
at the University of California, San Diego, CA and the Veterans Healthcare System following the International 
Association for the Study of Pain (IASP) Guidelines for Use of Animals in Research. Rats underwent surgery 
under deep anesthesia using isoflurane (5% initially and then 3% for maintenance during surgery). An incision 
was made in the skin of the back over the T2 spinous process. After clearing of the muscle, the dorsal aspect of 
the T3 vertebra was removed. The cord was compressed for 5 seconds using mosquito forceps locked completely 
closed. Thin forceps were used to bilaterally compress the cord at two sites in the center of the T3 spinal segment 
located 1 mm apart, as we described previously27. The muscles overlying the spinal cord were sutured and the 
skin incision was closed with surgical suture. Following surgery, rats were maintained in cages kept on heat pads 
(37 °C) for 1 week and received banamine (1 mg/kg) and ampicillin (0.2 mg/kg) in Ringer's lactate for three days. 
Bladder care was performed twice daily at 12-hour intervals for the first two weeks following surgery, and thereaf-
ter once daily until rats could urinate on their own, approximately four weeks after surgery. Bladders were always 
expressed prior to acclimation for behavioral testing. Rats were given amoxicillin their drinking water over the 
duration of the experiment to prevent bladder infections that could confound behavioral results.
SCI and grafting surgeries. Grafting human iPSC derived neural progenitor cells into rodent models of 
spinal cord injury was approved by the IACUC at UCSD. Rats were subjected to T3SCI as previously described27. 
We used T3SCI because this is the highest spinal level at which a severe spinal cord lesion allows subject survival; 
severe lesions located more rostral than T3 result in persistent forelimb dysfunction. This procedure is a modifi-
cation of the clip-compression model56. Two rats died after surgery. The remaining 36 rats were randomly divided 
into cohorts that received no cells with growth factor cocktail (n = 13), hiNPC (n = 11) or EI-tPA-treated hiNPC 
(n = 12). hiNPC were reconstituted in human fibrinogen (25 mg/ml, Sigma, F3879), and a cocktail of four growth 
factors: brain-derived neurotrophic factor (BDNF; 50 µg/ml, Peprotech, 452–02), basic fibroblast growth factor 
(bFGF; 10 μg/ml, Sigma, F0291), vascular endothelial growth factor, (VEGF, 10 µg/mL Peprotech 100–20), and 
a calpain inhibitor (MDL28170; 50 µM Sigma M6690) with or without EI-tPA (12 nM; Molecular Innovations). 
Immediately prior to injection into lesion sites, cells, fibrinogen and growth factor cocktails were mixed with 
rat thrombin (5U/ml, Sigma, T5772). Two injections were made into the lesion cavity. 1.5 million hiNPCs were 
grafted. Injections were stopped if reflux occurred. Treatments were initiated one week after T3SCI because at that 
time, acute inflammation is reduced and initiation of gliosis is minimized57.
RNASeq studies. Total RNA isolated from DRGs of rats grafted with hiNPC or from control rats that did not 
receive hiNPC were analyzed. The RNA was subjected to RNASeq using Illumina High Seq. Quality control of the 
raw fastq files was performed using the software tool FastQC. Sequencing reads were aligned to the Ensembl rat 
genome (Rnor_6.0) using the STAR v2.5.1a aligner58. Read quantification was performed with RSEM49 v1.3.0 and 
Ensembl annotation (Rattus_norvegicus.Rnor_6.0.92.gtf). The R BioConductor packages edgeR59 and limma60 
were used to implement the limma-voom61 method for differential expression analysis. The experimental design 
was modeled upon condition (~0 + condition). Contrasts were made between hiNPC and “no cell” groups.
Statistics. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software Inc.). All results 
are expressed as mean ± SEM. Differences between two treatment means were assessed by a Student's t-test. 
Differences between multiple treatment means were analyzed by a one-way ANOVA followed by Neuman Keuls 
or Tukey’s post hoc tests. Behavioral data including BBB and tactile allodynia assessments were analyzed by 
repeated measures ANOVA followed by Bonferroni’s post hoc test. P < 0.05 was considered statistically significant.
Data availability
For additional methods on hiNPC, immunoblotting, trypan blue exclusions studies, motor and sensory 
functional testing, and immunofluorescence microscopy please see Supplemental Experimental Procedures. The 
data sets generated during and/or analyzed during the current study are available from the corresponding author 
on reasonable request.
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